Zevra Therapeutics, Inc. $ZVRA Shares Purchased by Cantor Fitzgerald L. P.

Cantor Fitzgerald L. P. raised its stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 487.9% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 117,576 shares of the company’s stock after acquiring an additional 97,575 shares during the period. Cantor Fitzgerald L. P.’s holdings in Zevra Therapeutics were worth $1,118,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Royce & Associates LP acquired a new stake in Zevra Therapeutics during the 3rd quarter worth $6,574,000. Stonepine Capital Management LLC lifted its position in Zevra Therapeutics by 19.3% in the second quarter. Stonepine Capital Management LLC now owns 775,620 shares of the company’s stock valued at $6,833,000 after acquiring an additional 125,620 shares during the last quarter. Schroder Investment Management Group acquired a new position in Zevra Therapeutics in the second quarter valued at $2,779,000. Kingdon Capital Management L.L.C. boosted its stake in Zevra Therapeutics by 44.4% in the third quarter. Kingdon Capital Management L.L.C. now owns 650,000 shares of the company’s stock valued at $6,182,000 after acquiring an additional 200,000 shares in the last quarter. Finally, Legal & General Group Plc grew its holdings in shares of Zevra Therapeutics by 26.8% during the second quarter. Legal & General Group Plc now owns 935,677 shares of the company’s stock worth $8,243,000 after purchasing an additional 197,940 shares during the last quarter. Institutional investors and hedge funds own 35.03% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ZVRA. Wall Street Zen downgraded Zevra Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, March 14th. HC Wainwright set a $26.00 price target on Zevra Therapeutics in a research note on Tuesday, December 30th. Weiss Ratings raised Zevra Therapeutics from a “sell (d+)” rating to a “hold (c+)” rating in a research report on Tuesday, March 10th. BTIG Research started coverage on Zevra Therapeutics in a research note on Monday. They issued a “buy” rating and a $23.00 price objective for the company. Finally, Guggenheim set a $23.00 price objective on Zevra Therapeutics and gave the company a “buy” rating in a report on Tuesday, March 10th. Seven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $23.00.

Zevra Therapeutics Price Performance

Shares of NASDAQ:ZVRA opened at $9.55 on Thursday. Zevra Therapeutics, Inc. has a one year low of $6.19 and a one year high of $13.16. The stock has a market capitalization of $560.68 million, a price-to-earnings ratio of 7.18 and a beta of 0.91. The company has a 50-day simple moving average of $9.02 and a 200-day simple moving average of $9.10. The company has a debt-to-equity ratio of 0.40, a quick ratio of 5.63 and a current ratio of 5.68.

Insider Buying and Selling

In other Zevra Therapeutics news, insider Adrian W. Quartel sold 4,533 shares of the stock in a transaction that occurred on Friday, January 30th. The stock was sold at an average price of $8.83, for a total transaction of $40,026.39. Following the completion of the sale, the insider directly owned 9,723 shares of the company’s stock, valued at approximately $85,854.09. This trade represents a 31.80% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Neil F. Mcfarlane sold 91,000 shares of Zevra Therapeutics stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $9.38, for a total value of $853,580.00. Following the completion of the transaction, the chief executive officer owned 364,350 shares in the company, valued at $3,417,603. This trade represents a 19.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 114,158 shares of company stock valued at $1,062,878 in the last quarter. 2.40% of the stock is currently owned by insiders.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.